Clinique Pasteur

Running trials

• Not yet recruiting

  Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery

  NCT07766109· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Not yet recruiting

  First-in-Human Study of the Circle Safe System for Diaphragm Response Monitoring During Pulmonary Vein Ablation

  NCT07820631· Circle Safe, Inc.· Source

• Not yet recruiting

  AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

  NCT07604727· University Medical Center Groningen· Source

• Recruiting

  OPTION-EMEA Clinical Trial

  NCT07349121· Boston Scientific Corporation· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Recruiting

  Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

  NCT07462910· French Cardiology Society· Source

• Not yet recruiting

  Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial

  NCT07497750· University Hospital, Toulouse· Source

• Recruiting

  HeartLogic™ in Patients With Heart Failure.

  NCT07544771· Poitiers University Hospital· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

  NCT07299071· University Hospital, Bordeaux· Source

• Recruiting

  The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

  NCT07211126· Tandem Diabetes Care, Inc.· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  SpaceOAR Post-Market Registry Study

  NCT07300631· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France

  NCT07048795· mylife Diabetes Care AG· Source

• Active, not recruiting

  BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

  NCT07181590· Abbott Medical Devices· Source

• Active, not recruiting

  Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis

  NCT07116551· Abbott Medical Devices· Source

• Enrolling by invitation

  Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

  NCT06898086· Rede Optimus Hospitalar SA· Source

• Active, not recruiting

  A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

  NCT06808217· Boston Scientific Corporation· Source

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· UNICANCER· Source

• Recruiting

  Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

  NCT06861361· Ceric Sàrl· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· AstraZeneca· Source

• Recruiting

  Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

  NCT06825104· Volta Medical· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· The Leeds Teaching Hospitals NHS Trust· Source

• Recruiting

  Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology

  NCT06392997· ZIWIG· Source

• Recruiting

  Short versus long antiplatelet therapy after TAVI

  2023-508208-40-00· Phase 2/3· Centre Hospitalier Universitaire De Caen Normandie· Source

• Recruiting

  EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation

  NCT06738849· DiappyMed· Source

• Recruiting

  Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

  NCT06180382· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Active, not recruiting

  Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

  NCT06557889· Phase 2· Institut Claudius Regaud· Source

• Recruiting

  Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas

  2024-514875-16-00· Phase 2· Oncopole Claudius Regaud· Source

• Recruiting

  Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

  NCT06276465· Phase 3· UNICANCER· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source

• Recruiting

  PulseSelect™ PFA Global Registry

  NCT06393920· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

  NCT07777744· University Hospital, Basel, Switzerland· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

  NCT06419374· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

  NCT06204640· Phase 3· University Hospital, Caen· Source

• Recruiting

  Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

  NCT06207981· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Active, not recruiting

  Affera Global Registry

  NCT06026345· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation

  NCT06168370· Phase 4· St. Antonius Hospital· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Recruiting

  Evaluation of the Vivo Isar Stent System in Routine Clinical Practice

  NCT06420505· Translumina GmbH· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Charite University, Berlin, Germany· Source

• Active, not recruiting

  Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation

  NCT06083012· Volta Medical· Source

Showing 50 of 87.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation9 recruiting
• Aortic stenosis8 recruiting
• Heart failure4 recruiting
• Prostate cancer4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Ovarian cancer3 recruiting
• Type 1 diabetes3 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Lung cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Stroke2 recruiting
• Triple-negative breast cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Endometriosis1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Pancreatic cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Uterine fibroids1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Oxygenation Procedure for Obese Patients During Intubation in the Operating Room

  NCT06914401· Clinique Pasteur· Source

• Completed

  Medical and Sociological Characterization of the Population of Patients Admitted for a First Ablation of Atrial Fibrillation in the Occitanie Ouest Region

  NCT06618833· University Hospital, Toulouse· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· ARCAGY/ GINECO GROUP· Source

• Completed

  Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation

  NCT05940597· University Hospital, Grenoble· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Volta Medical· Source

• Completed

  Oxygen Therapy Remote Monitoring in COPD Patients.

  NCT05473780· Vivisol· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

  NCT05524324· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF)

  NCT05418725· University Hospital, Bordeaux· Source

• Completed

  Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access

  NCT05399680· Cordis US Corp.· Source

• Completed

  VALVOSOFT® Pivotal Study

  NCT05235568· Cardiawave SA· Source

• Completed

  Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

  NCT07580937· University of Chicago· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Ground-Breaking Electroporation-based Intervention for PAROXysmal Atrial Fibrillation Treatment (BEAT PAROX-AF)

  NCT05159492· University Hospital, Bordeaux· Source

• Completed

  Multicenter Validation of the Salivary miRNA Signature of Endometriosis

  NCT05244668· ZIWIG· Source

• Completed

  One Day Implantation Program for Heart Failure Patients Implanted With CRT-P

  NCT05142293· Biotronik SE & Co. KG· Source

• Completed

  Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

  NCT04753749· MicroPort CRM· Source

• Completed

  Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD

  NCT04774302· Clinique Pasteur· Source

• Completed

  HeartLogic France Study: Heart Failure Patients Managed with the HeartLogic Algorithm

  NCT04619888· Poitiers University Hospital· Source

• Completed

  Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

  NCT04702451· Volta Medical· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· University Hospital, Brest· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

  NCT03795298· Boston Scientific Corporation· Source

• Completed

  CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System

  NCT03699345· Edwards Lifesciences· Source

• Completed

  The TARGET BP OFF-MED Trial

  NCT03503773· Phase 2· Ablative Solutions, Inc.· Source

• Completed

  DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation

  NCT03643224· Medtronic Cardiac Ablation Solutions· Source

• Completed

  The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

  NCT03551496· Phase 3· Boston Scientific Corporation· Source

• Completed

  The TransCatheter Valve and Vessels Trial

  NCT03424941· Maatschap Cardiologie Zwolle· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Completed

  PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

  NCT03275506· Phase 2· ARCAGY/ GINECO GROUP· Source

• Completed

  FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System

  NCT03417011· Medtronic Cardiovascular· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source

• Completed

  SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

  NCT02439775· Medtronic Vascular· Source

• Completed

  Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

  NCT02539966· REVA Medical, Inc.· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

• Completed

  Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  NCT00673842· Phase 3· University of Calgary· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation48 works · 30 trials
• Aortic stenosis21 works · 17 trials
• Ventricular tachycardia9 works · 1 trial